Renal

Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency

0

studies recruiting now

as of 7 Sept 2026

1

studies registered in total

as of 7 Sept 2026

0

countries with a recruiting site

as of 7 Sept 2026

None

recruiting study posted to date

among recruiting studies

Recruiting trials

No recruiting trial found right now.

1 study is registered for Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency, but none was recruiting as of 7 Sept 2026. Here is what is still worth doing.

Keep watching

Get an email when a new Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

About Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (POR).

Treatments being studied

2 approved treatments and 6 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: Hydrocortisone (Acetasol hc)Approved: Crinecerfont (Crenessity)
Phase 2Fludrocortisone Acetate (Astonin)
Phase 2Tildacerfont
Phase 2Abiraterone Acetate (Abiraterone accord)
Phase 2Nevanimibe Hydrochloride
Phase 1/2Nifedipine (Adalat)
Phase 1Verucerfont

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).